Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Arena Pharmaceuticals (ARNA) -- Ignore unavailable to you. Want to Upgrade?

To: kenhott who wrote (706)	12/4/2006 9:57:56 AM
From: scaram(o)uche	Read Replies (1) \| Respond to of 2274

Hey, thanks! Been meaning to find that link and get to work. So.... "maximal efficacy will likely require co-administration of agents with multiple mechanistic targets". Sort of like fen/phen. 2C makes their chart, if not their pipe.

To: kenhott who wrote (706)	12/4/2006 8:22:20 PM
From: Biotech Jim	Read Replies (2) \| Respond to of 2274

Ken- Great find on the microsomal triglyceride transfer protein (MTP) program of PFE. Very interesting that they are in Ph2. There is some solid genetics on the MTP, and I have heard of impressive weight loss effects of such compound(s) in dog at least. This appears to be a very interesting first in class obesity target. One key question here is will an MTP inhibitor cause mechanistic? increases in LFTs. As a colleague of mine who is engaged in obesity drug discovery at big pharma said a few years back, "so many targets, so little time". BJ